Investigational Drug Details
| Drug ID: | D480 |
| Drug Name: | Guanabenz |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB00629 |
| DrugBank Description: | Guanabenz is an alpha-2 adrenergic agonist used to treat hypertension. |
| PubChem ID: | -- |
| CasNo: | 5051-62-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NC(N)=NN=CC1=C(Cl)C=CC=C1Cl |
| Structure: |
|
| InChiKey: | WDZVGELJXXEGPV-YIXHJXPBSA-N |
| Molecular Weight: | 231.082 |
| DrugBank Targets: | Alpha-2A adrenergic receptor agonist; Alpha-2B adrenergic receptor binder |
| DrugBank MoA: | Guanabenz's antihypertensive effect is thought to be due to central alpha-adrenergic stimulation, which results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature in addition to a decreased systolic and diastolic blood pressure and a slight slowing of pulse rate. Chronic administration of guanabenz also causes a decrease in peripheral vascular resistance. |
| DrugBank Pharmacology: | Guanabenz, a centrally acting α-2 adrenergic agonist, is indicated for treatment of hypertension. |
| DrugBank Indication: | For management of High blood pressure. |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (NCT05084404) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0017 | NCT05084404 | Phase 2 | Recruiting | No Results Available | October 14, 2021 | November 17, 2021 | Details |
| L0375 | JPRN-jRCT2031210380 | Phase 2 | Recruiting | No Results Available | 20/10/2021 | 7 February 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A06102 | 33007418 | Pharmacol Res | Endoplasmic reticulum stress and protein degradation in chronic liver disease. | Details |
| A06653 | 32792584 | Sci Rep | Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity. | Details |
| A49216 | 35820743 | BMJ Open | Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. | Details |